Biomarkers in colorectal cancer

被引：0
作者：
Ben Markman
Víctor Rodríguez-Freixinos
Josep Tabernero
机构：
[1] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO),Medical Oncology Department
[2] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO),Medical Oncology Department
来源：
Clinical and Translational Oncology | 2010年 / 12卷
关键词：
Colorectal cancer; Biomarkers; Chemotherapy; Targeted therapies;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Systemic therapies available for treatment of colorectal cancer have increased in recent years, leading to improved clinical outcomes. However, a significant proportion of patients fail to derive meaningful benefits, whereas others suffer from unacceptable toxicities. Therefore, not only does the search for novel and effective anticancer agents continue, there is also a pressing need to optimise the use of all treatments in the therapeutic armamentarium. In addition to knowledge gleaned from well-designed and relevant clinical trials, increasing effort is being invested into biomarkers. The identification and implementation of validated biomarkers has the potential to further our understanding of the biology of colorectal cancer and also to greatly improve the efficiency with which cancer treatments are administered.
引用
收藏
页码：261 / 270
页数：9
相关论文
共 185 条
  • [1] Atkinson A.J.(2001)Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 89-95
  • [2] Colburn W.A.(2005)Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 124 169-174
  • [3] DeGruttola V.G.(2006)ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol 24 5313-5327
  • [4] Chen C.C.(1998)A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer Cancer Res 58 5248-5257
  • [5] Yang S.H.(2005)Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol 23 609-618
  • [6] Lin J.K.(2007)Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J Clin Oncol 25 767-772
  • [7] Locker G.Y.(2008)Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials J Clin Oncol 26 abstr 4008-257
  • [8] Hamilton S.(2003)Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N Engl J Med 349 247-1821
  • [9] Harris J.(2009)Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803 J Clin Oncol 27 1814-221
  • [10] Boland C.R.(1994)Allelic loss of chromosome 18q and prognosis in colorectal cancer N Engl J Med 331 213-1732
12345678910